Locally Advanced or Metastatic Breast Cancer
Conditions
Keywords
locally advanced or metastatic breast cancer, peripheral neuropathy, chemotherapy-induced peripheral neuropathy, eribulin
Brief summary
Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of eribulin-induced PN in adult participants treated with eribulin in a real-life setting with locally advanced or metastatic breast cancer (MBC) who have progressed following at least one and up to three chemotherapeutic regimens for advanced disease.
Interventions
DRUGEribulin
Sponsors
Eisai GmbH
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced or MBC with progression after at least one chemotherapeutic regimen for advanced disease eligible for treatment with eribulin according to Fachinformation. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless participants were not suitable for these treatments * 1-3 prior chemotherapeutic regimens for advanced disease * Age \>=18 years at the time of Informed Consent * Ability to understand and willingness to respond to questions related to their health * Decision for the participant to start treatment with eribulin has been made prior to inclusion in this study. * Signed written Informed Consent
Exclusion criteria
* Previous treatment with eribulin in any line of treatment * Contraindication according to the Fachinformation of eribulin * Pregnancy or lactation * Participation in an interventional clinical trial at the same time
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of therapeutic interventions (e.g., analgesics) being used to treat eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Percentage of resolved cases in participants who experience eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | A resolved case is defined as one that ended or returned to baseline as determined by CTCAE grade version 4.0 |
| Time to resolution of eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | Time to resolution is defined as the time from onset (or worsening from baseline) to the date of resolution (defined as stop of PN or return to baseline), as determined by CTCAE grade version 4.0. |
| Percentage of participants who discontinued eribulin treatment due to eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Time to eribulin treatment discontinuation due to eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Number of resolved cases in participants who experience eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | A resolved case is defined as one that ended or returned to baseline as determined by CTCAE grade version 4.0 |
| Number of participants experiencing eribulin-induced peripheral neuropathy (PN) | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Percentage of participants experiencing eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Number of participants with the indicated grade of eribulin-induced PN, as determined by Common Terminology Criteria for Adverse Events (CTCAE), grade version 4.0 | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Percentage of participants who experienced dose modifications of eribulin treatment due to eribulin-induced PN | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Health-related quality of life scores measured using the EuroQOl-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Time to disease progression | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | Time to disease progression is defined as the time from the start of eribulin treatment to Investigator assessment of disease progression (clinical or radiological) |
| Number of participants with any serious adverse event (SAE) and number of participants with any non-serious AE | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Percentage of participants with any SAE and percentage of participants with any non-serious AE | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
| Health-related quality of life scores measured using the Patient Neurotoxicity Questionnaire | Approximately 15 months, or until death or resolution of peripheral neuropathy, or return to baseline level, whichever comes first | — |
Countries
Germany
Outcome results
None listed